Metabolic & Weight Loss
Lixisenatide
Adlyxin; Lyxumia; AVE0010
1 min read · Updated July 27, 2026 · 3 references
Curated by PeptideInfo Wikilast reviewed how we verify
A short-acting GLP-1 receptor agonist with a nuanced product history: U.S. approval and current label records coexist with the commercial withdrawal of the EU Lyxumia authorization.
Evidence: Regulator-approved drug with human trial evidence.
Approved in: FDA approval history (United States; Adlyxin) and approved fixed combination products; EU Lyxumia authorization withdrawn in 2025 at sponsor request for commercial reasons
- A short-acting GLP-1 receptor agonist with a nuanced product history: U.S. approval and current label records coexist with the commercial withdrawal of the EU Lyxumia authorization.
- It increases glucose-dependent insulin secretion, suppresses glucagon and markedly slows gastric emptying, reducing post-meal glucose excursions.
- The label warns about pancreatitis, serious hypersensitivity, hypoglycemia with insulin or secretagogues, kidney injury during severe gastrointestinal reactions and gallbladder disease. ELIXA showed cardiovascular non-inferiority, not superiority.
A short-acting GLP-1 receptor agonist with a nuanced product history: U.S. approval and current label records coexist with the commercial withdrawal of the EU Lyxumia authorization.
Overview
A short-acting GLP-1 receptor agonist with a nuanced product history: U.S. approval and current label records coexist with the commercial withdrawal of the EU Lyxumia authorization.
Primary regulatory source
This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.
Identity and mechanism
It increases glucose-dependent insulin secretion, suppresses glucagon and markedly slows gastric emptying, reducing post-meal glucose excursions.
PubChem CID 90472060; C215H347N61O65S; 4858 Da.
Regulatory label facts
FDA approval history (United States; Adlyxin) and approved fixed combination products; EU Lyxumia authorization withdrawn in 2025 at sponsor request for commercial reasons.
The dose below reproduces a regulator-approved label; it is not a treatment recommendation. Adlyxin label: 10 micrograms subcutaneously once daily for 14 days, then 20 micrograms once daily, within one hour before the first meal.
Safety boundary
The label warns about pancreatitis, serious hypersensitivity, hypoglycemia with insulin or secretagogues, kidney injury during severe gastrointestinal reactions and gallbladder disease. ELIXA showed cardiovascular non-inferiority, not superiority.
This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.
References
Frequently asked questions
- What is Lixisenatide?
- A short-acting GLP-1 receptor agonist with a nuanced product history: U.S. approval and current label records coexist with the commercial withdrawal of the EU Lyxumia authorization.
- Is Lixisenatide approved as a medicine, and where?
- It is an approved prescription medicine, but where it is approved matters: FDA approval history (United States; Adlyxin) and approved fixed combination products; EU Lyxumia authorization withdrawn in 2025 at sponsor request for commercial reasons. It should only be used under medical supervision.
- What is Lixisenatide studied for?
- Lixisenatide is most often discussed in the context of approved peptide medicines — verification pilot. Being studied for an area does not mean it is proven or approved for it.
- Does Lixisenatide have human clinical trials?
- Yes. Lixisenatide has been studied in human clinical trials and is an approved medicine in at least some regions.
Educational disclaimer. This article summarizes published research for informational purposes and is not medical advice. Lixisenatide is an approved medicine within the stated approval scope (FDA approval history (United States; Adlyxin) and approved fixed combination products; EU Lyxumia authorization withdrawn in 2025 at sponsor request for commercial reasons) and must only be used under medical supervision; research-grade or unprescribed material is not a lawful substitute. Consult a qualified healthcare professional before making health decisions.